TITLE

ABBOTT/EUROPROTEOME TO DEVELOP BREAST CANCER TESTS

PUB. DATE
April 2004
SOURCE
Worldwide Biotech;Apr2004, Vol. 16 Issue 4, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the research collaboration between Abbott Laboratories and Europroteome AG for the discovery of in vitro diagnostic tests for the early detection of breast cancer for use on Abbott's automated instrument systems. Goal of the program; Terms of the agreement; Expectations of Edward L. Michael, president of Abbott Molecular Diagnostics, on the collaboration.
ACCESSION #
12714977

 

Related Articles

  • Microscopic changes may double risk of breast cancer. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);02/20/99, Vol. 318 Issue 7182, p483 

    Reports that scientists in Great Britain have determined that a microscopic change in breast tissue may double the risk of breast cancer in some women. Implication of the results; Biopsies reviewed by researchers; Comments from Doctor Nadine Tung, director of the cancer risk and prevention...

  • Customize Starting Age and Frequency of Mammograms.  // Radiology Today;Aug2011, Vol. 12 Issue 8, p34 

    The article reports on the study which suggests that mammograms should be scheduled on a personalized basis as determined by factors such as a woman's age, her family history of breast cancer, and the density of her breasts.

  • Abbott staff show a healthy interest in new flex scheme. Washington, Tom // Employee Benefits;Aug2009, p6 

    The article reports on the interest of the staff on the new flexible benefits plan and online reward statements (TRS) launched by the global healthcare and medical research firm Abbott. The flex scheme offers staff for extra benefits and allows the employees to buy and sell . A...

  • Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. Clarke, Michael J // BMJ: British Medical Journal (International Edition);10/31/98, Vol. 317 Issue 7167, p1246 

    Describes the hierarchy of evidence needed to determine treatment efficacy from case reports. Information on case reports, case series, comparison with historical groups, randomized trials and systematic reviews; Hierarchy of evidence on ovarian ablation for breast cancer; Conclusions.

  • Ed Michael on Abbott: Then and now. Farrell, Patrick // MLO: Medical Laboratory Observer;Oct2007, Vol. 39 Issue 10, p32 

    The article profiles Edward L. Michael, executive vice president for diagnostics of broad-based healthcare company Abbott. Michael states the dramatic moments encountered by the company, the innovations made in their laboratory instruments, and the shortage of clinical lab scientists. He...

  • Diagnosis and Management of Male Breast Cancer. Lanitis, Sophocles; Rice, Alexandra J.; Vaughan, Alexander; Cathcart, Paul; Filippakis, George; Al Mufti, Ragheed; Hadjiminas, Dimitri J. // World Journal of Surgery;Nov2008, Vol. 32 Issue 11, p2471 

    Male breast cancer (MBC) is rare with an incidence of 1% of all breast cancers. The evidence about the treatment is derived from the data on the management of the female breast cancer because conduction of randomized, controlled trials is impossible due to the rarity of the disease. In this...

  • Do breast implants influence the detection/prognosis of breast cancer?  // Contemporary OB/GYN;Apr2004, Vol. 49 Issue 4, p13 

    The article discusses research being done on the influence of breast implants on the detection of breast cancer. It references a study by D. L. Miglioretti, C. M. Rutter, B. M. Geller, et al, in the 2004 issue of "Journal of the American Medical Association."

  • Breast cancer patient stories project. Tanna, Nuttan; Buijs, Helene; Pitkin, Joan; Reichert, Robert // Menopause International;Dec2012, Vol. 18 Issue 4, p128 

    Objective. It is estimated that there are almost half a million women living with or beyond a breast cancer diagnosis in the UK, often referred to as the breast cancer survivor population. We report on the setting up of a dedicated breast cancer and menopause symptoms service (BCMS), and present...

  • Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Leek, R.D.; Landers, R.J.; Harris, A.L.; Lewis, C.E. // British Journal of Cancer;2/15/99, Vol. 79 Issue 5/6, p991 

    Necrosis is a common feature of invasive carcinoma of the breast and is caused by chronic ischaemia leading to infarction. Although necrosis was previously assumed to be due to a generally poor blood supply in the tumour, in this study we show that it is present in tumours with focal areas of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics